Feature | Heart Valve Technology | November 17, 2020

TAVR Is Now Dominant Form of Aortic Valve Replacement in the United States

Data from the STS/ACC TVT Registry provides insights on state of TAVR, outcomes steadily improving

The Edwards Lifesciences Sapien 3 TAVR valve. The annual volume of TAVR has increased each year and in 2019 TAVR volume (72,991) exceeded all forms of SAVR (57,626), coinciding with the U.S. Food and Drug Administration (FDA) approval of TAVR for low-risk patients. 

November 17, 2020 — Since the approval of the first transcatheter aortic valve replacement (TAVR) device in 2011, more than 276,000 patients have undergone a TAVR procedure in the United States. According to a report from The Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) TVT Registry, volumes have increased every year. In 2019 TAVR exceeded all forms of surgical aortic valve replacement (SAVR) for the first time. 

In addition, over time the 30-day mortality and stroke rates have decreased, while pacemaker need remains largely unchanged. The full report was published Monday in the Journal of the American College of Cardiology and The Annals of Thoracic Surgery simultaneously.[1]

“The STS/ACC TVT Registry allows us to see major trends occurring in the real-world TAVR patient population, including a rapid growth in both the number of hospital sites performing TAVR and case volume as we treat a broader spectrum of patients. We have also seen TAVR become the leading choice for aortic valve replacement compared to the open surgical approach,” said John D. Carroll, M.D., chair of the STS/ACC TVT Registry Steering Committee and the lead author on the report. “Furthermore, the data on outcomes after TAVR document a substantial improvement in quality of care in the last nine years.”

Since the first TAVR device approval, access has been extended from patients considered inoperable or at extreme risk (2011), at high-risk (2012), intermediate-risk (2016) and low-risk (2019) for SAVR. Researchers examined data in the STS/ACC TVT Registry for all TAVR procedures performed at sites active through 2019. An early TAVR experience was defined as patients treated from late 2011 through 2013 and was compared to current TAVR experience, which was defined as patients treated in 2019.

Data in 2019 are from hospitals located in 49 U.S. states, as well as two sites in the District of Columbia and two sites in Puerto Rico. In August 2020 there were 715 U.S. TAVR sites. As of the opening of a site in Wyoming in 2020 TAVR programs exist in all 50 states. The only U.S. TAVR sites not included in the STS/ACC TVT Registry are those in military hospitals and the Veterans Authority (VA) medical system: as of mid-2019 there were eight VA TAVR programs.

Watch the related VIDEO: Tracking Transcatheter Valve Outcomes in the STS-ACC TVT Registry — Interview with John Carroll, M.D.

TAVR Procedure Volumes In the Unites States

The annual volume of TAVR has increased each year and in 2019 TAVR volume (72,991) exceeded all forms of SAVR (57,626), coinciding with the U.S. Food and Drug Administration (FDA) approval of TAVR for low-risk patients. The number of TAVR procedures performed per site varies, but as the number of sites performing TAVR has increased, the total annual volume has increased. In 2019 sites performed 84 TAVR procedures on average with 161 sites performing less than 50 cases. An expert consensus document published by stakeholders — including the ACC and STS — ncluded a recommendation of a 50-case annual threshold minimum for sites performing TAVR.

TAVR Patient Demographic Statistics

Data showed the median age of patients undergoing TAVR has slightly gone down from early TAVR experiences. In 2019 mostly males (56%) underwent TAVR, a shift away from the early TAVR period when there was a nearly equal male/female distribution of patients undergoing the procedure. For all years, patients undergoing TAVR were predominantly white with the persistence of under-representation of blacks, based on overall U.S. demographics, at 4% despite the substantial growth of sites offering TAVR. This finding will stimulate further research into its possible causes ranging from barriers to health care access to differences in the prevalence of disease. From 2011 thru 2018 extreme and high-risk patients remain the largest cohort undergoing TAVR, but in 2019 intermediate-risk was the largest cohort. In 2019, the first year TAVR was FDA-approved for low-risk patients, this population made up 11.5% of all TAVR patients and had a median age of 75.

Smaller TAVR Sheaths Allowed Large Increase in Femoral Access Procedures

In the early TAVR period with very large vascular sheaths required for the first-generation TAVR delivery catheters, only 57.1% of TAVR procedures used femoral artery access. By the current TAVR period in 2019, femoral access accounted for 95.3% of vascular access sites for the procedure. In 2019 the axillary-subclavian was the most commonly used alternative access approach, a shift from the use of transapical and direct aortic approaches that were the common alternative access point in the early TAVR period.

TAVR Length of Stay

The median length of stay for patients has declined from seven days to two days for all patients over the course of the report. For patients assessed as low-risk, the median length of stay in 2019 was only one-day—an overnight hospital stay—with some patients discharged the same day. In the early TAVR period, most patients were discharged to another care facility. In 2019 90.3% of patients were discharged home, while 6.6% were discharged to a rehabilitation or extended care facility and 2.45% to a nursing home. 

U.S. TAVR Mortality, Stroke and Pacemaker Rates

Researchers also found a steady and dramatic shift in mortality from the early TAVR period to 2019. In-hospital mortality fell from 5.4 to 1.3% and 30-day mortality decreased from 7.2 to 2.5%. In-hospital and 30-day stroke rates also fell from the early TAVR period to the current TAVR period. However, the 30-day pacemaker implantation rate has remained largely the same. The in-hospital rate has fallen in the context of the shorter length of stay at the hospital.

TAVR Quality of Life Assessments

The STS/ACC TVT Registry has been innovative in gathering data from patients on their assessment of their individual health status, using the Kansas City Cardiomyopathy Questionnaire (KCCQ) before treatment. The registry also gathers data on whether there are changes post-TAVR in component metrics on quality of life (QOL), functional state and other patient reported outcomes. In 2018 — the most recent year with one-year outcomes data for patients treated on or before Sept. 30 — 80.7%  of all patients who were alive at one-year post-TAVR and had complete KCCQ data reported a good QOL. In addition, a subgroup analysis revealed that this benchmark was achieved in 77.7% of high-extreme risk, 83.6% of intermediate-risk and 85.8% of low-risk patients.

According to the researchers, this report also provides a preliminary real-world assessment of patients having TAVR who were classified as being low-risk after the FDA approved these patients for TAVR in August 2019.

Related TAVR Content:

VIDEO: Tracking Transcatheter Valve Outcomes in the STS-ACC TVT Registry — Interview with John Carroll, M.D.

U.S. TAVR Outcomes Need Improvement Based on TVT Registry Analysis

Boston Scientific Pulls Lotus Edge TAVR Valve Off The Market

FDA Approves TAVR for Low-risk Patients Creates A Paradigm Shift in Cardiology

TAVR Expected to See Rapid Growth in Next 5 years

Boston Scientific Launches Acurate neo2 Transcatheter Aortic Valve System in Europe

Acurate neo TAVR Valve Fails to Meet Noninferiority With Medtronic CoreValve Evolut

VIDEO: Interventional Structural Heart Advances Are Rapidly Expanding — Interview with Juan F. Granada, M.D.

Boston Scientific Launches Acurate neo2 Transcatheter Aortic Valve System in Europe

TAVR Non-Inferior to Surgery in U.K. Review of Surgery vs. TAVR

Find more TAVR news


1. John D. Carroll, Michael J. Mack, Sreekanth Vemulapalli, et al. STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2020 Nov, 76 (21) 2492–2516.

Related Content

News | Cardiovascular Business

September 15, 2023 — The American College of Cardiology (ACC) has recognized five Hackensack Meridian Health hospitals ...

Home September 15, 2023
Feature | Cardiovascular Business | By Emily Gilbert and Kamran Zamanian, PhD

The global interventional cardiology device market is driven by the number of procedures performed across the globe. The ...

Home September 12, 2023
News | Cardiovascular Business

September 11, 2023 — The Heart Rhythm Society (HRS) is gearing up for its second annual HRX event, bringing ...

Home September 11, 2023
News | Cardiovascular Business

September 11, 2023 — Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging ...

Home September 11, 2023
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

As we wind down the summer months, DAIC takes a look at the Top 10 most-read pieces of content from www.dicardiology.com ...

Home August 31, 2023
Feature | Cardiovascular Business

August 22, 2023 — Leaders at University Hospitals (UH) Harrington Heart & Vascular Institute are saddened to share news ...

Home August 22, 2023
News | Cardiovascular Business

August 17, 2023 — MemorialCare, a prominent nonprofit Southern California integrated health system, announced today that ...

Home August 17, 2023
News | Cardiovascular Business

August 10, 2023 — It is the position of SCAI that ABIM diplomates who successfully pass their exams and report ...

Home August 10, 2023
News | Cardiovascular Business

August 2, 2023 — Dr. Doria Scortichini, MD FACC joins the growing Auburn Heart Institute that is affiliated with Auburn ...

Home August 02, 2023
News | Cardiovascular Business

August 1, 2023 — Hackensack Meridian Health hospitals are being recognized for their readiness to respond and care for ...

Home August 01, 2023
Subscribe Now